Formulary management of low molecular weight heparins. - Wikidata - awgldk - TriplyDB

Formulary management of low molecular weight heparins.

Formulary management of low molecular weight heparins.

http://www.wikidata.org/entity/Q33881653

about

Outcomes of dalteparin use following total knee arthroplasty: a retrospective analysis.

P2860

Q43266408-47991C12-E26E-40CB-87C0-5F1C19DA28F6

P2860

Formulary management of low molecular weight heparins.

http://www.wikidata.org/entity/Q33881653

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Formulary management of low molecular weight heparins.

@ast

Formulary management of low molecular weight heparins.

@en

type

label

Formulary management of low molecular weight heparins.

@ast

Formulary management of low molecular weight heparins.

@en

prefLabel

Formulary management of low molecular weight heparins.

@ast

Formulary management of low molecular weight heparins.

@en

P1433

Q33881653-A1FB7FEC-D784-489F-926B-62C7F8C0C970

P1476

Q33881653-C36F1D08-585E-4510-AE1A-2CA7B991DA54

P2093

Q33881653-037F0556-18AB-407E-8A1F-17BB3C214F86

Q33881653-32EDC119-854F-462F-93BB-A4B953FDF171

Q33881653-3F465C47-692F-4DA0-9E36-BE6ED2A7C073

Q33881653-55C26FD9-FC1E-447F-A39F-2150B5C7A462

Q33881653-BBEA3FBF-1DBA-4D07-A676-28B0B0F28D9F

Q33881653-CA51B016-FA6F-48EB-81DB-2633C400FCEB

P2860

Q33881653-14A265F7-BAE0-4230-AE99-472124964641

Q33881653-15153BE7-D0B7-486F-8948-53CC01C299FB

Q33881653-3C941228-5285-44B5-AD6B-412216A35A72

Q33881653-5CB0AA53-FDA6-4045-8948-D27612E9CD28

Q33881653-62DB3297-5247-4304-B0C7-77502801DA7D

Q33881653-74432440-30A9-47E7-8AD4-6926389D5D49

Q33881653-8099234C-5832-420F-8A49-0F4780A51726

Q33881653-A871AB23-0D90-4E14-B035-6F8F391C1018

Q33881653-AA2D491F-5BF2-44F7-B9EE-D8C14994D30F

P2888

Q33881653-726716BB-EC9F-4A46-88C3-F5F7B8492189

P304

Q33881653-B2267D4B-62CB-4DD1-8F94-1E8E7D2842D4

P31

Q33881653-FD4412B6-558D-4C7C-A5D1-93F23DC3E128

P356

Q33881653-F8665D73-37B0-4C4F-89C0-F557CC5CB225

P433

Q33881653-9CA8373D-A59C-4A96-BFB6-245705DBD134

P478

Q33881653-E1646DD9-6CC9-4D58-93D1-C26159E9D554

P577

Q33881653-618B9457-1300-41CF-A29E-8800EB01BCB5

P6179

Q33881653-33AF1AF0-AFB6-42AD-ADFF-4A4D3AF46E09

P698

Q33881653-4ACA4B9D-E2A4-4455-B509-283924C6DFF5

P356

00019053-200017010-00001

P1433

PharmacoEconomics

P1476

Formulary management of low molecular weight heparins.

@en

P2093

Chisoholm MA

http://www.w3.org/2001/XMLSchema#string

Kotzan JA

http://www.w3.org/2001/XMLSchema#string

Martin BC

http://www.w3.org/2001/XMLSchema#string

Perri M

http://www.w3.org/2001/XMLSchema#string

Spruill WJ

http://www.w3.org/2001/XMLSchema#string

Wade WE

http://www.w3.org/2001/XMLSchema#string

P2860

Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group.

Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty.

Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients.

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial.

Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.

Prevention of thromboembolism after spinal cord injury using low-molecular-weight heparin.

Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin.

P2888

00019053-200017010-00001

P304

1-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/00019053-200017010-00001

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1014995656

http://www.w3.org/2001/XMLSchema#string

P698

10747761

http://www.w3.org/2001/XMLSchema#string